Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It?
Jonnalagadda, Venu Gopal, Char, Harish Prabhanna, Ankana, Praveen KumarLanguage:
english
Journal:
Cardiovascular Drugs and Therapy
DOI:
10.1007/s10557-018-6779-9
Date:
March, 2018
File:
PDF, 297 KB
english, 2018